Johnson & Johnson (NYSE:JNJ) Shares Sold by WealthPLAN Partners LLC

WealthPLAN Partners LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 42,185 shares of the company’s stock after selling 2,955 shares during the period. Johnson & Johnson comprises approximately 0.9% of WealthPLAN Partners LLC’s holdings, making the stock its 28th largest holding. WealthPLAN Partners LLC’s holdings in Johnson & Johnson were worth $6,101,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. AMF Tjanstepension AB grew its stake in Johnson & Johnson by 14.2% during the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock worth $68,985,000 after buying an additional 52,997 shares during the last quarter. Alpha Financial Partners LLC bought a new position in Johnson & Johnson during the 3rd quarter worth $209,000. Wealth Group Ltd. bought a new position in Johnson & Johnson during the 3rd quarter worth $213,000. Swedbank AB grew its stake in Johnson & Johnson by 5.3% during the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock worth $358,980,000 after buying an additional 111,570 shares during the last quarter. Finally, Schaper Benz & Wise Investment Counsel Inc. WI grew its stake in shares of Johnson & Johnson by 1.8% in the third quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 97,483 shares of the company’s stock worth $15,798,000 after purchasing an additional 1,768 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several recent analyst reports. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Wolfe Research initiated coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target for the company. Wells Fargo & Company decreased their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Raymond James cut their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Finally, Bank of America cut their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Trading Down 0.7 %

Shares of NYSE JNJ opened at $156.20 on Tuesday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a market cap of $376.08 billion, a price-to-earnings ratio of 23.49, a P/E/G ratio of 2.46 and a beta of 0.52. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The business has a fifty day simple moving average of $147.87 and a 200-day simple moving average of $155.95.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the business earned $2.29 EPS. Sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.18%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ? increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.